Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
2.840
-0.120 (-4.05%)
Apr 23, 2025, 11:39 AM EDT - Market open
Adverum Biotechnologies Stock Forecast
ADVM's stock price has decreased by -74.43% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Adverum Biotechnologies stock have an average target of 25.83, with a low estimate of 5.00 and a high estimate of 40. The average target predicts an increase of 809.51% from the current stock price of 2.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Adverum Biotechnologies stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $40 → $33 | Strong Buy | Maintains | $40 → $33 | +1,061.97% | Apr 17, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $10 → $5 | Hold | Maintains | $10 → $5 | +76.06% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +956.34% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +956.34% | Nov 19, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $12 → $10 | Hold | Maintains | $12 → $10 | +252.11% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
12.88M
from 1.00M
Increased by 1,187.80%
Revenue Next Year
307.02K
from 12.88M
Decreased by -97.62%
EPS This Year
-4.77
from -6.62
EPS Next Year
-4.25
from -4.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105.0M | 948,150 | 136.5M | ||
| Avg | 12.9M | 307,020 | 26.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10,400.0% | -92.6% | 44,359.6% | ||
| Avg | 1,187.8% | -97.6% | 8,594.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.22 | -0.18 | 0.09 | ||
| Avg | -4.77 | -4.25 | -3.84 | ||
| Low | -6.08 | -6.42 | -7.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.